FDA approval: Kebilidi (from Catapult's regulatory round-up for November 2024)
FDA has approvedeladocagene exuparvovec-tneq (Kebilidi) a recombinant adeno-associated virus serotype 2 (rAAV2)-based gene therapy, containing the human DDC gene (dopa decarboxylase) indicated for the treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. It is designed to correct the underlying genetic defect by delivering a functioning DDC gene directly into the putamen, increasing the AADC enzyme and restoring dopamine production. AADC defi...
Publication Details
- Journal
- Industrias Culturais (Universidade de Coimbra)
- Published
- 2025-02-12
- DOI
- https://doi.org/10.58079/13axk
- Primary Topic
- Hydraulic flow and structures
- Type
- article
- Field-Weighted Citation Impact
- 0.00